Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up
Berit Jordan(Martin Luther University Halle-Wittenberg), Karin Jordan(OhioHealth), Fátima Cardoso(Université Paris Cité), Patrick Jahn, Martin Taphoorn(Leiden University Medical Center), Matthias Preusser(Comprehensive Cancer Center Vienna), Florian Scotté(University of Derby), Émilie Le Rhun(University of Zurich), Anita Margulies(European Society for Paediatric Oncology), Guido Cavaletti(University of Milano-Bicocca), Hege Sagstuen Haugnes(University Hospital of North Norway)
Cited by 319
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k